Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Mark Rumbak

Pulmonary Disease Tampa, FL Medical Doctor

NPI 1609967058 CMS profile 164264

13330 Usf Laurel Dr, Tampa, FL 33612

Open in the dashboard

General payments

$528,271

475 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Mark Rumbak of Tampa, FL is reported in the CMS Open Payments database as having received $528,271 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $3,000 1
2020 General $143,137 90
2019 General $382,134 384

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Rumbak
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Mark Rumbak were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Mark Rumbak Pulmonary Disease median Middle half National median
2019 $382,134 $377 $109–$1,340 $163
2020 $143,137 $230 $56–$907 $114
2021 $3,000 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. GlaxoSmithKline, LLC. $185,966 132 payments
  2. Mallinckrodt Enterprises LLC $94,499 53 payments
  3. United Therapeutics Corporation $56,897 52 payments
  4. Mallinckrodt Hospital Products Inc. $37,680 12 payments
  5. Genentech USA, Inc. $34,195 42 payments
  6. Insmed, Inc. $32,891 41 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $24,032 22 payments
  8. Janssen Pharmaceuticals, Inc $18,328 20 payments
  9. Mylan Specialty L.P. $10,304 13 payments
  10. Actelion Pharmaceuticals US, Inc. $9,523 22 payments
  11. Other $23,957 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $456,624 147 payments
  2. Travel and Lodging $34,993 106 payments
  3. Consulting Fee $20,060 8 payments
  4. Food and Beverage $12,987 210 payments
  5. Grant $3,000 1 payment
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $600 1 payment
  7. Gift $4 1 payment
  8. Education $4 1 payment
Products named General payments · program years 2019–2021
  1. TRELEGY ELLIPTA $150,771 100 payments
  2. ACTHAR Autoimmune And Rare Disease $92,031 51 payments
  3. REMODULIN $38,372 34 payments
  4. TYVASO $38,372 34 payments
  5. ACTHAR Immunology $37,680 12 payments
  6. ORENITRAM $33,727 29 payments
  7. ANORO $29,651 22 payments
  8. Esbriet $28,592 39 payments
  9. Arikayce $22,810 29 payments
  10. XARELTO $18,328 20 payments
  11. Other $68,610 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record